Janux Therapeutics Inc Ownership
$16.30
2.28%
Nasdaq, Sep 25, 04:00 pm EDT.
Closed.
Janux Therapeutics Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
RA Capital Management, LP
|
11.190m | 18.32% | — | Mar 31 2026 |
| 2 |
Janus Henderson Investors
|
4.196m | 6.87% | -1.154m | Mar 31 2026 |
| 3 |
BlackRock Institutional Trust Company, N.A.
|
3.985m | 6.52% | +547.674k | Mar 31 2026 |
| 4 |
Prosight Capital
|
3.550m | 5.81% | +399.030k | Mar 31 2026 |
| 5 |
Point72 Asset Management, L.P.
|
3.070m | 5.03% | +1.914m | Apr 28 2026 |
|
1
RA Capital Management, LP
|
18.32%
11.190m
|
|
2
Janus Henderson Investors
|
6.87%
4.196m
|
|
3
BlackRock Institutional Trust Company, N.A.
|
6.52%
3.985m
|
|
4
Prosight Capital
|
5.81%
3.550m
|
|
5
Point72 Asset Management, L.P.
|
5.03%
3.070m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 42.55% of Janux Therapeutics Inc, with RA Capital Management, LP the biggest at 18.32%, followed by Janus Henderson Investors (6.87%) and BlackRock Institutional Trust Company, N.A. (6.52%). |
Recent Janux Therapeutics Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Sep 26 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 23 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 19 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 14 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 08 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 01 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Sep 26 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 23 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 19 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 14 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 08 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 01 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Janux Therapeutics Inc Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Janux Therapeutics Inc has fallen over the past 12 months from around 19.9% to 12.3% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
